Loading organizations...
Lycera has raised $47.0M across 2 funding rounds.
Key people at Lycera.
Lycera has raised $47.0M in total across 2 funding rounds.
Lycera was a biopharmaceutical company developing small molecule immunomodulatory medicines. Its core technology focused on designing novel compounds to precisely modulate immune responses for therapeutic benefit. The company advanced a proprietary pipeline of these small molecules, aiming to address significant unmet medical needs through targeted immunological interventions.
Gary Glick, a chemistry professor at the University of Michigan, founded Lycera in 2006. The company emerged as a spinout from the university, driven by the insight that small molecule therapeutics could offer precise control over immune pathways. Glick’s vision was to translate academic research into innovative treatments.
Lycera directed its efforts toward patients suffering from autoimmune diseases and various forms of cancer. The company's mission was to pioneer and deliver novel immunomodulatory therapies, offering new hope and improved outcomes for individuals with complex immunological conditions. Its vision aimed to establish a leading presence in precision immune-based medicine.
Lycera has raised $47.0M across 2 funding rounds. Most recently, it raised $11.0M Series A Extension in April 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 28, 2010 | $11M Series A Plus | Jeffrey Leiden | — | Announced |
| May 1, 2009 | $36M Series A | — | ARCH Venture Partners, Canaan Partners, Jeffrey Leiden, EDF Ventures, Nina Kjellson | Announced |
Lycera is a biopharmaceutical company headquartered in Ann Arbor, Michigan, focused on developing small-molecule therapies to treat cancer and autoimmune diseases by modulating the immune response through immune metabolism, cell signaling, and immune cell differentiation.[1][2] It advances a proprietary portfolio of small molecules, either suppressing or activating immune responses, with programs targeting conditions like inflammatory bowel disease (e.g., lead candidate LYC-30937, planned for clinical testing in 2015), ulcerative colitis, arthritis, and broader autoimmune disorders; the company has collaborated with Merck and maintains a drug pipeline including Phase 2 assets like parimifasor (discontinued for ulcerative colitis) and preclinical/pending candidates targeting F1F0-ATPase, RORγt, and ATPase modulators.[1][4] Lycera serves patients with unmet needs in oncology and immunology, solving challenges in immune dysregulation via novel immunomodulators, with early revenue around $6.9 million and about 30 employees as of available records.[1]
Lycera emerged as a biotech innovator in Ann Arbor, leveraging world-class expertise in complementary research areas to build its immune-focused pipeline, though specific founding year and founders are not detailed in available sources.[1] Key early milestones include establishing collaborations with Merck for autoimmune therapies and advancing wholly owned programs, such as LYC-30937 for inflammatory bowel disease, set for clinical entry in early 2015; the leadership team brings deep drug discovery, development, commercialization experience, and ties to global thought leaders.[1] Investors like InterWest Partners provided backing, fueling growth amid a tech stack including Automattic, PHP, Google, and Cloudflare tools.[1] The company gained traction through its pipeline, with clinical trials starting as early as 2016 (e.g., December 5 and 1) and a 2018 program launch, positioning it within Michigan's life sciences ecosystem like the Michigan Life Sciences & Innovation Center.[2][4]
Lycera rides the wave of precision immunology, capitalizing on advances in small-molecule immunomodulation amid rising demand for targeted therapies in autoimmune diseases and oncology, where immune checkpoint and metabolic modulators address limitations of biologics like high costs and delivery challenges.[1][2][3] Timing aligns with post-2010s biotech booms in oral small molecules for immunology (e.g., JAK inhibitors' success), amplified by collaborations like Merck's, which de-risk development and tap big pharma resources.[1] Market forces favoring Lycera include aging populations driving autoimmune/cancer prevalence, regulatory pushes for oral alternatives, and Michigan's life sciences hubs fostering innovation; it influences the ecosystem by pioneering RORγt and ATPase targets, contributing to pipeline diversity and secondary market liquidity via platforms like Forge Global.[2][4][5]
Lycera's path forward hinges on resurrecting or partnering dormant pipeline assets like parimifasor (post-Phase 2 discontinuation) and pending RORγt programs, potentially via new trials or acquisitions in a consolidating biotech sector hungry for immune modulators.[4][5] Trends like AI-driven drug design, combination immunotherapies, and oral drug dominance will shape its trajectory, especially if it leverages its Ann Arbor base for talent and funding amid secondary market interest.[1][5] Influence may evolve through buyouts by majors like Merck successors or IPOs if milestones hit, amplifying its role in underserved immunology niches—echoing its core mission to transform immune disease treatment from the ground up.[1]
Key people at Lycera.
Lycera has raised $47.0M in total across 2 funding rounds.
Lycera's investors include Jeffrey Leiden, ARCH Venture Partners, Canaan Partners, EDF Ventures, Nina Kjellson.
